206 related articles for article (PubMed ID: 21054)
1. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
Cunningham JL; Shen DD; Shudo I; Azarnoff DL
Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
Aitio ML; Allonen H; Kanto J; Mäntylä R
Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
[TBL] [Abstract][Full Text] [Related]
3. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
[TBL] [Abstract][Full Text] [Related]
4. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
Haughey DB; Lima JJ
Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
Karim A; Kook C; Novotney RL; Zagarella J; Campion J
Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
[TBL] [Abstract][Full Text] [Related]
6. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
Bryson SM; Whiting B; Lawrence JR
Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284
[TBL] [Abstract][Full Text] [Related]
7. Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
Giacomini KM; Blaschke TF
Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():42-8. PubMed ID: 6705426
[TBL] [Abstract][Full Text] [Related]
8. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
Hasselström J; Enquist M; Hermansson J; Dahlqvist R
Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
[TBL] [Abstract][Full Text] [Related]
9. Disopyramide concentrations in saliva.
Aitio ML; Virtanen R; Lammintausta R
Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
Johnston A; Henry JA; Warrington SJ; Hamer NA
Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
Le Corre P; Gibassier D; Sado P; Le Verge R
Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of disopyramide in patients with chronic renal failure.
Francois B; Mallein R; Rondelet J; Lussignol M
Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
Lima JJ; Boudoulas H; Shields BJ
Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
[TBL] [Abstract][Full Text] [Related]
14. Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats.
Karim A; Kook C; Campion J; Doherty M
Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):222-36. PubMed ID: 921413
[TBL] [Abstract][Full Text] [Related]
15. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.
Cook CS; Karim A; Sollman P
Drug Metab Dispos; 1982; 10(2):116-21. PubMed ID: 6124395
[TBL] [Abstract][Full Text] [Related]
16. The influence of protein binding on disopyramide clearance.
Bryson SM; Lawrence JR; Steele WH; Campbell BC; Elliott HL; Sumner DJ
Eur J Clin Pharmacol; 1982; 23(5):453-6. PubMed ID: 7151851
[TBL] [Abstract][Full Text] [Related]
17. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
Burk M; Peters U
Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetic and metabolic study of disopyramide in oral and intravenous administration].
De Graeve J; Kremers P; Gielen JE
Therapie; 1977; 32(2):195-204. PubMed ID: 898127
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics of disopyramide administered by intramuscular, intravenous and oral routes to normal volunteers [proceedings].
Ashford JJ; Carmichael D; Kidner PH
Br J Pharmacol; 1979 Jul; 66(3):442P-443P. PubMed ID: 526732
[No Abstract] [Full Text] [Related]
20. The absorption of disopyramide in animals determined using a stable isotope co-administration technique.
Haskins NJ; Waddell KA; Ford GC; Spalton PN; Walls CM; Forrest TJ; Palmer RF
Biomed Mass Spectrom; 1980 Feb; 7(2):80-3. PubMed ID: 7407335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
